DK0990440T3 - Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid - Google Patents

Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid

Info

Publication number
DK0990440T3
DK0990440T3 DK98905636T DK98905636T DK0990440T3 DK 0990440 T3 DK0990440 T3 DK 0990440T3 DK 98905636 T DK98905636 T DK 98905636T DK 98905636 T DK98905636 T DK 98905636T DK 0990440 T3 DK0990440 T3 DK 0990440T3
Authority
DK
Denmark
Prior art keywords
octylphenyl
saccharide
lecithin
diol
propane
Prior art date
Application number
DK98905636T
Other languages
English (en)
Inventor
Atsushi Sakai
Rumiko Masuda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0990440T3 publication Critical patent/DK0990440T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98905636T 1997-02-27 1998-02-25 Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid DK0990440T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4366897 1997-02-27
PCT/JP1998/000755 WO1998037875A1 (fr) 1997-02-27 1998-02-25 Composition medicamenteuse

Publications (1)

Publication Number Publication Date
DK0990440T3 true DK0990440T3 (da) 2009-02-23

Family

ID=12670236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98905636T DK0990440T3 (da) 1997-02-27 1998-02-25 Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid

Country Status (18)

Country Link
US (1) US6277888B1 (da)
EP (2) EP0990440B1 (da)
JP (1) JP4153563B2 (da)
KR (1) KR20000075745A (da)
CN (1) CN1178653C (da)
AT (1) ATE412407T1 (da)
AU (1) AU735406B2 (da)
BR (1) BR9811453A (da)
CA (1) CA2282378C (da)
DE (1) DE69840169D1 (da)
DK (1) DK0990440T3 (da)
ES (1) ES2317663T3 (da)
IL (1) IL131608A (da)
NZ (1) NZ337823A (da)
PT (1) PT990440E (da)
RU (1) RU2188004C2 (da)
SI (1) SI0990440T1 (da)
WO (1) WO1998037875A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
RU2330839C2 (ru) * 2002-01-11 2008-08-10 Санкио Компани, Лимитед Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
DE202004021680U1 (de) * 2003-04-08 2010-04-22 Novartis Ag Feste pharmazeutische Zusammensetzung
RU2233163C1 (ru) * 2003-04-30 2004-07-27 Государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт" Способ лечения акантолитической пузырчатки
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
TWI355934B (en) 2004-02-24 2012-01-11 Sankyo Co Pharmaceutical composition for treatment or prophy
PT1773307E (pt) * 2004-07-30 2015-01-14 Novartis Ag Formulações de compostos à base de 2-amino-1,3- propanodiol
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
NZ588372A (en) * 2005-09-09 2012-03-30 Novartis Ag Diphenyl ether or thioether derivatives for treatment of autoimmune diseases
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
PT2465492E (pt) 2007-10-12 2015-10-15 Novartis Ag Composições que compreendem moduladores de receptores de esfingosina-1-fosfato (s1p)
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
WO2013020069A1 (en) * 2011-08-03 2013-02-07 Ma Zhongmin Treatment of type 2 diabetes with fty720
WO2015015254A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612993B2 (da) 1973-09-03 1981-03-25
US4020159A (en) * 1974-10-08 1977-04-26 Apotheker A. Herbert K.G., Fabrik Pharmazeutischer Praparate Wiesbaden Methods of and medications for treating cardiac disorders by using strophanthin
JPS5562010A (en) * 1978-10-31 1980-05-10 Ajinomoto Co Inc Fat emulsion for intravenous injection
AU5078885A (en) * 1984-12-20 1986-06-26 Warner-Lambert Company Non-irritant detergent
JPS61172814A (ja) * 1985-01-25 1986-08-04 Ss Pharmaceut Co Ltd 安定な低溶血性ビタミンｅ注射液
JPS63152327A (ja) * 1987-11-20 1988-06-24 Toyama Chem Co Ltd 脂肪乳剤から成る溶血防止用組成物を含有する製剤
JPH01172814A (ja) 1987-12-26 1989-07-07 Canon Inc レーザーユニット
AU6461090A (en) 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JPH04173736A (ja) * 1990-11-06 1992-06-22 Nippon Shinyaku Co Ltd 乳化剤
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
JP3870419B2 (ja) 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
JP3169807B2 (ja) 1995-09-18 2001-05-28 本田技研工業株式会社 ロータ組み付け装置
ATE279185T1 (de) * 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
KR100190826B1 (ko) * 1996-08-26 1999-06-01 강재헌 적혈구 용혈 억제용 약제학적 조성물 및 그의제조방법

Also Published As

Publication number Publication date
JP4153563B2 (ja) 2008-09-24
AU6115598A (en) 1998-09-18
RU2188004C2 (ru) 2002-08-27
IL131608A0 (en) 2001-01-28
EP0990440B1 (en) 2008-10-29
US6277888B1 (en) 2001-08-21
DE69840169D1 (de) 2008-12-11
EP2030614A1 (en) 2009-03-04
PT990440E (pt) 2009-02-05
SI0990440T1 (sl) 2009-04-30
CN1178653C (zh) 2004-12-08
HK1027039A1 (en) 2001-01-05
AU735406B2 (en) 2001-07-05
CA2282378A1 (en) 1998-09-03
IL131608A (en) 2003-02-12
EP0990440A4 (en) 2004-04-21
NZ337823A (en) 2001-04-27
KR20000075745A (ko) 2000-12-26
WO1998037875A1 (fr) 1998-09-03
ATE412407T1 (de) 2008-11-15
ES2317663T3 (es) 2009-04-16
BR9811453A (pt) 2000-09-12
EP0990440A1 (en) 2000-04-05
CN1253499A (zh) 2000-05-17
CA2282378C (en) 2008-12-30
HK1027959A1 (en) 2001-02-02

Similar Documents

Publication Publication Date Title
BR9811453A (pt) Composição farmacêutica
PT1050301E (pt) Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol
AU1172997A (en) 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders
UY23665A1 (es) Procedimiento para la preparacion de compuesto farmaceutico
RU99120398A (ru) Фармацевтическая композиция
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
ATE220542T1 (de) Zweiteilige kapsel zur aufnahme von pharmazeutischen zubereitungen für pulverinhalatoren
RU99123047A (ru) Производное 2-аминопропан-1,3-диола, его фармацевтическое применение и промежуточные продукты для их синтеза
EA199901107A1 (ru) Системы и устройства для лечения переломов костей или больных костей с помощью расширяемых тел (варианты), стерильный набор инструментов для введения в кость (варианты)
EP0276317A4 (en) GAMMA-L-GLUTAMYL-L-CYSTEINE ETHYL ESTER AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT.
RU92016244A (ru) Производные сахарина-ингибиторы протеолитических ферментов
ATE316779T1 (de) Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
ITRM940570A0 (it) "sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
ITRM940571A0 (it) "sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
BR9810452A (pt) Nova combinação de medicamentos contra asma
RU96113317A (ru) Способ постановки ирригационной системы в теноново пространство
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
FI952953A7 (fi) Aineita metabolisten luustosairauksien hoitamiseen
NO20001895D0 (no) Anvendelse av glykosaminoglykaner for fremstilling av farmasøytiske preparater for behandling av diabetes assosierte- øyesykdommer
DK0704219T3 (da) Anvendelse af faktor for osteoblastisk celledeling
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
PT88984A (pt) Processo para a preparacao de embonato de azelastina e de composicoes farmaceuticas que o contem como ingrediente activo
IL110888A (en) Pharmaceutical compositions for the treatment of liver diseases comprising a vasodilating compound
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.
SE9002435D0 (sv) Medel samt foerfarande foer behandling av biologisk implantationsvaevnad